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Abstract 
Tuberculosis remains one of the major causes of global death from a single infectious agent. This situation is worsened by the HIV/AIDS 
pandemic because one-third of HIV/AIDS patients are co-infected with Mycobacterium tuberculosis. Failure to control the spread of 
tuberculosis is largely due to our inability to detect and treat all infectious cases of pulmonary tuberculosis in a timely manner, allowing 
continued M. tuberculosis transmission within communities. Diagnosis of tuberculosis can be made using indirect and direct methods. The 
indirect tests, such as interferon-gamma release assays, provide a new diagnostic method for M. tuberculosis infection, but do not 
discriminate between infection and active disease. The most common direct method for diagnosing TB worldwide is sputum smear 
microscopy (developed more than 100 years ago), where bacteria are observed in sputum samples examined under a microscope. In countries 
with more developed laboratory capacities, cases of tuberculosis may also be diagnosed using culture methods (the current gold standard) or, 
increasingly, using rapid molecular tests. In this review, we discuss the traditional methods for the diagnosis of tuberculosis. We also discuss 
other inexpensive assays that can be used to detect the presence of M. tuberculosis. 
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Introduction 
Tuberculosis (TB) is an ancient infectious disease 
caused by Mycobacterium tuberculosis (MTB) that 
typically affects the lungs (pulmonary TB), but can 
affect other sites as well (extrapulmonary TB). The 
disease is spread in the air when people who are sick 
with pulmonary TB expel bacteria by, for example, 
coughing. In general, 10% of people infected with 
MTB will go on to develop TB disease, whereas in 
90% of the cases the subjects are asymptomatic and 
non-infectious because the host immune system 
contains the tubercular infection [1]. In these subjects, 
the infection persists in a latent form for the lifetime of 
the individual. Conditions such as HIV, malnutrition, 
and inflammatory diseases, which all require 
immunosuppressive drugs, may cause a latent 
tubercular infection (LTBI) to become an active TB 
infection [1]. In 2010, there were an estimated 8.8 
million incident cases of TB (ranging between 8.5 
million and 9.2 million) globally, equivalent to 128 
cases per 100,000 of the population [2]. The greatest 
amount of the estimated number of cases in 2010 
occurred in Asia (59%) and Africa (26%); smaller 
proportions of cases occurred in the Eastern 
Mediterranean Region (7%), Europe (5%) and the 
Americas (3%) [2]. Of the 8.8 million cases of TB in 
2010, 5.7 million were diagnosed and reported to 
national TB control programmers (NTPs). Among 
notified cases, there were an estimated 290,000 cases 
of multidrug-resistant TB (MDR-TB), of which only 
53,000 (18%) were reported to have been diagnosed 
and enrolled in appropriate treatment [3]. Earlier and 
improved detection of TB and expanded capacity to 
diagnose cases of MDR-TB are thus global priorities 
for TB control. Diagnosis of tuberculosis can be made 
using direct and indirect methods. Indirect diagnosis 
can identify the subjects infected with MTB, but the 
assays that are now available do not discriminate 
between LTBI and active TB; consequently, diagnosis 
of active TB is still made using sputum smear 
microscopy, isolating MTB and identifying specific 
MTB DNA sequences.  
 
Indirect diagnosis of tuberculosis 
Tuberculin skin test 
Historically, the diagnosis of tubercular infection 
was made using the tuberculin reaction test, also 
known as the Mantoux intradermal reaction. 
Tuberculin was developed over 100 years ago by 
Robert Koch and consists of a mixture of 
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approximately 200 purified proteins derivative (PPD) 
present in MTB but found also in Mycobacterium 
bovis Bacilli Calmette-Guerin (BCG) strain (used in 
vaccination) and in many environmental mycobacteria. 
Since its discovery, the PPD has been used to diagnose 
latent TB infection. When the PPD is injected 
intracutaneously, a classic delayed hypersensitivity 
reaction occurs in infected subjects, which manifests 
in vivo as a dermal infiltrate. The intradermal reaction 
may be indicative of a positive PPD reaction (when a 5 
mm diameter in infants or immunocompromised 
subjects and a 10 mm diameter in adults is observed) 
or of a negative response. Unfortunately, the 
tuberculin skin test (TST) has several limitations: it 
has a low sensitivity, and the antigenic cross-reactivity 
resulting from the distribution of many antigens in 
BCG and in environmental mycobacteria is 
responsible for its low specificity. Consequently, a 
positive reaction can be indicative not only of contact 
with MTB but also of previous vaccination with BCG 
or contact with environmental mycobacteria. False 
positive results may also be caused by repeated tests as 
a consequence of the boosting effect of continuous 
sensitization with PPD. These different limits of the 
TST have encouraged scientists to develop an 
alternative assay that could overcome the PPD defects. 
 
Interferon-gamma release assays (IGRAs) 
Interferon-gamma release assays (IGRAs) provide 
a new diagnostic method for MTB infection based on 
detection of the interferon-gamma (IFN-γ) response to 
the TB antigens, which includes early secretory 
antigenic target-6 (ESAT-6), cultures filtered protein-
10 (CFP-10), and a third antigen called TB7.7. These 
antigens are encoded by genes of region of difference-
1 (RD1) which is present in MTB complex but absent 
in BCG and in most non-tuberculous mycobacteria 
(NTM). Two commercial IGRAs are now available: 
the enzyme-linked immunosorbent assay (ELISA)-
based QuantiFERON-TB Gold In-Tube assay (QFT-
GIT) and its predecessor, the QuantiFERON-TB Gold 
(QFT-G) test (Cellestis Ltd., Carnegie, Australia), in 
which interferon-gamma (IFN-g) is measured 
quantitatively by ELISA, and, the ELISpot-based T-
SPOT.TBTM test (Oxford Immunotec Inc., Abingdon, 
UK) in which the number of IFN-gamma-producing T 
cells is measured by ELISPOT. The performance of 
IGRAs has been examined in numerous studies of 
immunocompetent subjects, HIV-infected individuals, 
and children. Overall, the data in the literature 
indicates that both IGRAs have a better specificity and 
correlation with exposure to MTB than the TST and 
equal or greater sensitivity [4]. The greater specificity 
of IGRAs in comparison to the TST is very important 
for the correct identification of infected subjects and 
for the administration of preventive therapy. In 
particular, this is very useful in immunocompromised 
subjects such as HIV patients and individuals with 
inflammatory disease. Overall, data indicate that 
sensitivity and specificity of both IGRAs in HIV-
infected people is suboptimal when used alone to rule 
in or rule out active tuberculosis disease. HIV-
associated immunosuppression, measured by 
circulating CD4+ T-lymphocytes, negatively affects 
the performance of QFT-GIT [5], and to a lesser 
extent, T-SPOT.TB. Moreover, the decrease in 
sensitivity of IGRAs in HIV-infected patients is 
largely due to high rates of indeterminate results that 
are due either to a high-background production of 
IFN-γ (negative control) or to a failure test caused by 
an insufficient number of peripheral blood 
mononucleated cells. Data concerning the performance 
of IGRAs in patients with inflammatory disease are 
limited and sometimes discordant. Recently, it was 
demonstrated that immunosuppressive treatment 
affected the TST result more than the IGRA result; to 
optimize the sensitivity of the diagnosis of tubercular 
infection, both assays should be used in these subjects 
[6]. However, considering the greater specificity of 
IGRAs over TSTs, immunological assays are 
preferable in areas where BCG coverage is high to 
avoid unnecessary preventive tubercular therapy. 
Concordance between IGRAs and TSTs in children is 
good; both tests may be used for diagnosis of 
tubercular infection in pediatric cases, but it seems that 
tubercular infection is detected more quickly by IGRA 
than the TST [7]. Moreover, immunological assays are 
not affected by the boosting effect and therefore can 
be used in a serial manner [7]. Screening to diagnose 
tubercular infection should be periodically assessed by 
the health workers who are at risk of tubercular 
infection. In these subjects, the results of TSTs and 
IGRAs were discordant due to the BCG vaccination 
that is obligatory in the health sector. The best 
strategy, in economic terms, is the one that provides 
the initial screening with the tuberculin test and then 
the execution of the IGRAs in all the subjects with 
positive skin tests. Studies of the diagnostic value of 
IGRAs in the diagnosis of active TB indicate that their 
sensitivity is not different from that of the tuberculin 
test and that IGRAs are not recommended as tests used 
to predict active tuberculosis [8]. IGRAs are an 
improvement over TSTs; they are less prone to false 
positives caused by non-tuberculous mycobacteria or 
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BCG, have an internal control, and do not require a 
follow-up visit to assess the reaction. However, their 
main limitations, as for the PPD, is that they are not 
able to discriminate between latent infection and 
active disease, and may not be used to monitor the 
effectiveness of tuberculosis therapy. It is likely that 
IGRAs, through the inclusion of new antigens of MTB 
in addition to those of RD1 region, may become a 
powerful means of diagnosis able to differentiate 
between latent tubercular infection and active disease. 
 
Direct diagnosis 
Direct diagnostic activity involves isolation of 
mycobacteria, species-level identification, and the 
determination of the isolated strain’s drug sensitivity. 
Microbiological diagnosis of tuberculosis usually 
requires specific reagents, non-routine methods, more 
time, and more safety laboratory equipment related to 
bacteriological diagnostics. The specimens submitted 
for mycobacterial culture include a wide variety of 
different bodily fluids and tissues from various sites: 
sputum, urine, cerebral spinal fluid, aspirated gastric, 
tissue biopsy, or other samples from areas where the 
presence of TB infection is suspected. Ideally, the 
specimens should be obtained over three consecutive 
days, as a sample can be negative one day and positive 
the next. Mycobacteria are slow-growing and have an 
extended generation time (20 to 22 hours) compared to 
other bacteria (40 to 60 minutes); overgrowth of 
culture by other bacteria and fungi can occur in 
specimens obtained from non-sterile sources. The high 
lipid content of the cell wall makes mycobacteria more 
resistant to strong acids and alkalis compared with 
other bacteria. This property has been used to develop 
the decontamination procedures with sodium 
hydroxide or chlorhexidine to eliminate commensal 
flora microorganisms while keeping the mycobacteria 
viable [9]. Once the samples have been 
decontaminated, they may be cultured and analyzed 
through microscopic and molecular examinations. 
Table 1 shows the different methods for direct 
diagnosis of TB with sensitivity, specificity, and the 
cost of commercial and non-commercial assays.  
 
Direct microscopic examination 
MTB is an acid-fast bacillus (AFB). Acid 
resistance is one of the main features of mycobacteria 
that allows for quick identification. The sensitivity and 
specificity of direct examination after coloration for 
the diagnosis of pulmonary tuberculosis ranges 
between 50% and 80% and 84.9% and 99.5%, 
respectively, in positive cultures. AFB sputum smear 
microscopy is inexpensive and rapid but it has several 
drawbacks including low sensitivity and significant 
differences in performance depending on the operator. 
Consequently, sputum culture remains the gold 
standard for TB diagnosis. 
 
Isolation and culture 
Culture remains the most sensitive method for the 
detection of MTB in clinical specimens and it is the 
gold standard for the isolation of the tubercular 
Table 1: Direct methods of diagnosing tuberculosis 
Method Sensitivity (range) Specificity (range) 
Cost in US dollar USD 
(range) 
Microscopical examination 50-80% 84.9-99.5% 0.50 
Isolation and culture    
- Commercial (MGIT 960 system) 80-98.1% 89.6-100% 16-32 
- Non-commercial (LJ, MODS, NRA, LRP) 85-97% 93-100% 4.56-11.13 
Molecular identification    
- Commercial (Amplicor MTB, Cobas Taq 
Man MTB, BD Probetec ET, GeneXpert 
MTB/RIF) 
77-100% 91.3-100% 25-30 
- In-house NAAT 84-100% 83-100% 10 
Susceptibility testing    
- Commercial (MGIT 960, Line Probe 
assay, Genotype MTB Dr plus) 
75-98.1% 92-100% 15-56 
- No commercial (MODS, NRA, LRP, etc.) 72-100% 91-100% 1.40-4.00 
Other tests    
- LAM test 6-81% 88-100% 3.50 
- Immunochromatografic assays 95.2-99.6% 97.6-100% 2.03 
- Cricetomys rats 72-100% 92.23% - 
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bacillus. Culture is capable of detecting as few 101 102 
organisms/mL of specimen, surpassing the sensitivity 
of smear microscopy. While a number of culture 
options exist for clinical mycobacteriology 
laboratories, broth-based detection methods are 
preferable for the initial isolation of organisms from 
specimens. The liquid culture media is Middlebrook 
7H9 and requires an automatized incubator allowing 
incubation with an atmosphere containing 5% to 10% 
of CO2 and a regular and automatized detection of 
bacterial growth. 
Different incubator system have been developed. 
The Bactec TB-460 device (Becton-Dickinson, 
Franklin Lakes, USA) was the first semi-automatized 
system introduced in 1980 for the inoculation of 
mycobacteria. This system uses a radiometric method 
for the detection of mycobacterial growth; however, 
disposal of the radioactive waste produced by this 
system presents a logistical problem and increases 
costs. In the last decade, several other manufacturers 
have marketed various tools for the automatized 
detection of MTB growth in laboratories, such as the 
Bactec 9000MB (Becton-Dickinson), the Bactec 
Mycobacterial Growth Indicator Tube 960 (MGIT 
960, Becton Dickinson, Franklin Lakes, USA), the 
ESP Culture System II (Trek Diagnostic Systems, Sun 
Prairie, USA), and MB/Bact Alert 10 3D (Biomérieux, 
Craponne, France). Some are based on colorimetric 
methods that detect bacterial CO2 production, such as 
the MB/BacT ALERT 3D System; others use pressure 
sensor or fluorometric methods to detect bacterial O2 
consumption, such as the ESP Culture System II and 
BACTEC MGIT 960 System and Bactec 9000MB, 
respectively. Numerous studies have favorably 
valuated the non-radiometric isolation system; 
generally, it has been observed that MGIT 960 showed 
the lowest detection time for MTB growth, with a 
mean of days that varies between 10 and 15 [10]. It 
has been reported that its sensitivity varies between 
80% and 98.1% and its specificity varies between 
89.6% and 100%. The MGIT 960 system is also used 
extensively for the antibiotic sensitivity in vitro test, 
and data obtained from different studies have shown 
that this system is a reliable and effective way to 
quickly determine the sensitivity to anti-tuberculosis 
drugs of a tubercular isolated strain [11].  
Solid media are made of agar, egg, and malachite 
green to limit the growth of remaining contaminants 
(Lowenstein, Stonebrink, or Ogawa medium). The 
Middlebrook 7H10 and 7H11 media are semi-
synthetic agar media for MTB culture under an 
atmosphere containing 10% CO2. They are completely 
transparent and thus facilitate the early identification 
of MTB colonies.  
Liquid media are considered the gold standard for 
the isolation of MTB culture and have a significant 
rapidity (between 10 and 14 days) and a better quality 
of isolation compared to solid media [12]; however, 
solid media still play an important role in the isolation 
of mycobacteria from clinical samples and are 
recommended for use alongside a liquid medium by 
the Center for Disease Control. Because liquid systems 
may fail to recover all mycobacteria, it is essential that 
standard solid-based culture methods be used in 
conjunction with automated systems to ensure 
recovery of Mycobacterium spp. that such systems 
may not detect. 
Some simple manual TB culture-based methods 
are used with increasing frequency in developing 
countries. Among these are the microscopic 
observation of broth culture, nitrate reductase assay 
(NRA), luciferase reporter mycobacteriophage assay 
(LRP).  
Microscopic observation of broth cultures is a low-
technology but rapid testing method for tuberculosis 
[13]. When coupled with drug sensitivity testing, this 
assay has been called microscopic observation of drug 
sensitivity (MODS). MODS is a non-commercial TB 
liquid-culture method that is recommended by the 
World Health Organization for detection and drug 
susceptibility testing of MTB [14]. It is based on the 
observation of the cord formation of MTB grown in a 
liquid medium. Decontaminated sputum samples are 
inoculated into a 7H9 liquid medium in 24-well plates 
with or without antibiotics and incubated at 37°C in a 
CO2 incubator. Plates are read using an inverted 
microscope to identify the typical MTB cord 
formation. Data in the literature indicates that MODS 
is an optimal alternative method for timely and 
affordable identification of MDR-TB in resource-
limited settings.  Chaiyasirinroje et al. analyzed 202 
sputum samples of clinically diagnosed TB patients 
with MODS assay in relation to gold standard 
BACTECT MGIT 960 and Ogawa solid culture. The 
median time to culture positivity by MODS, solid, and 
liquid culture were 12, 30, and 6 days, respectively 
[15]. In another study conducted in Egypt, 115 smear-
positive TB patients were simultaneously tested using 
MODS and the BACTECT MGIT 960. In this study, 
MODS detected 112 (97.4%) positive samples for 
MTB, and BACTEC MGIT detected 115 (100%) [16]. 
More recently, the diagnostic accuracy of MODS was 
estimated against a reference standard including 
Löwenstein-Jensen (LJ) media and BACTEC MGIT 
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culture. Overall MODS sensitivity for MTB detection 
was 85% and specificity was 93%; the authors also 
demonstrated that diagnostic accuracy did not 
significantly differ by HIV infection status [17]. The 
NRA is based on the ability of MTB to reduce nitrate 
to nitrite by the action of the nitrate reductase enzyme, 
which is indicated by the development of a dark rose 
to purple-rose color after the addition of the reagent. 
This method enables the rapid detection of bacterial 
growth [18]. 
 The LRP assay is based on infection of MTB with 
phages harboring the luciferase gene. Viable 
mycobacteria will allow replication of the phages and 
production of light in the presence of cellular ATP 
when the substrate luciferin is added to the medium. 
Tests based on luciferase reporter phages have not 
been extensively evaluated. LRP assay proved 
comparably efficient to MGIT 960 at detecting MTB 
in a median of three days and with a sensitivity of 
97%. 
 
Molecular detection of M. tuberculosis 
Molecular detection of MTB continues to change 
the landscape of TB diagnostics. Because of the slow 
growth rate of MTB, conventional methods for its 
detection, based on solid culture media, take several 
weeks to yield results. The introduction of liquid 
culture-based techniques was a great improvement for 
diagnosis, shortening the time to detection to about 10-
14 days instead of the weeks that are needed when 
using conventional media. With the purpose of 
obtaining faster results and earlier diagnosis of 
tuberculosis, several molecular detection methods 
were introduced and have been evaluated in numerous 
studies. MTB-specific nucleic acid amplification tests 
(NAATs) are the most frequently used molecular tests 
for laboratory diagnosis of tuberculosis. Many in-
house PCR methods have been proposed and many 
studies have been published describing their 
application for tuberculosis diagnosis [19,20]. In-
house NAA tests use different targets, either DNA or 
RNA genus or species-specific targets, followed by a 
detection step performed on agarose or acrylamide 
gels, or hybridization in various formats. The most 
commonly used target for identification of MTB is the 
insertion sequence IS6110 present in 4 to 20 copies of 
more than 95% of MTB strains [21]. Overall, the 
reported sensitivity and specificity are in the range of 
84%-100% and 83%-100%, respectively in respiratory 
specimens. Lower sensitivity and specificity were 
observed in no respiratory samples. NAAT are also 
commercially available from different sources: the 
first two and oldest in the market are the Amplicor 
Mycobacterium tuberculosis test (Amplicor) (Roche 
Diagnostic Systems Inc, Indianapolis, USA) and the 
Amplified Mycobacterium Tuberculosis Direct Test 
(MTD) (Gen-Probe Inc, San Diego, USA). The 
Amplicor MTB test is a DNA-based test that amplifies 
a segment of the 16SrRNA gene using genus-specific 
primers that are detected in a colorimetric reaction in a 
micro-well plate format. An automated version of the 
test is the Cobas Amplicor MTB test, which allows 
automation of the amplification and detection in one 
system. Recently, the COBAS TaqMan MTB test was 
introduced using real-time PCR. Sensitivity and 
specificity of the Amplicor MTB test was higher in 
respiratory samples and ranged between 83% and 
92.4% and 91.3% and 100%, respectively. The 
Amplified MTD uses isothermal amplification of 16S 
ribosomal transcripts, which are detected in a 
hybridization protection assay with an acridinium 
ester-labeled MTB complex-specific DNA probe. 
Interpretation of results requires the use of a 
luminometer. Sensitivity ranged from 77% to 100%. 
BDProbe Tec ET is another commercial amplification 
method for the direct detection of MTB in clinical 
respiratory samples. It is based on a strand-
displacement amplification, a technique of isothermal 
amplification that uses enzymatic replication of target 
sequences IS6110 and the 16S rRNA gene. The most 
significant advance toward a molecular test for 
tuberculosis has come in the field of nucleic acid 
amplification with the launch of the GeneXpert 
MTB/RIF assay (Cepheid, Sunnyvale, USA) [22]. The 
GeneXpert multifunctional diagnostic platform is an 
automated closed system that performs real-time PCR, 
producing results in less than two hours. The assay 
simultaneously detects MTB and rifampin (RIF) 
resistance by PCR amplification of five overlapping 
probes that are complementary to the entire 81 base 
pair RIF resistance-determining region of the MTB 
rpoB gene, and subsequently probes this region for 
mutations that are associated with RIF resistance [23]. 
The PCR amplification process is hemi-nested, and the 
amplified target is detected in real time by six color 
fluorescent molecular beacons. The test is easy to use 
and does not require special training other than very 
basic computer knowledge. Assay sensitivity is higher 
than that of smear microscopy and close to that of 
culture [24]. When testing a single sputum sample, the 
assay detects 98%-100% of sputum smear-positive 
disease and 57%-83% of smear-negative disease 
among prospectively studied tuberculosis suspects 
[25]. In addition, the assay is useful in diagnosing 
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extrapulmonary tuberculosis from a range of samples 
from extrapulmonary sites, with sensitivities of 53%-
95% [26]. The assay is also highly specific with no 
cross-reaction with non-tuberculous mycobacteria or 
normal flora of the respiratory tract. Despite the high 
sensitivity and specificity, several studies have since 
detected numbers of false-positive resistance when 
compared with other testing methods and rpoB gene 
sequencing [27] in settings with a prevalence of low 
RIF resistance. The current WHO implementation 
guide recommends use of a second testing method to 
confirm RIF resistance in these settings and to test for 
resistance to second-line drugs whenever multidrug 
resistance is detected [28]. Molecular methods, based 
on species-specific DNA probes that hybridize to 
rRNA, have also been developed for rapid 
identification of mycobacteria. The first of these 
methods was AccuProbe (Gen-Probe, Bedford, USA), 
which, with a sensitivity and specificity of more of 
90%, identified MTB complex, Mycobacterium avium 
complex, Mycobacterium kansasii, and 
Mycobacterium gordonae. More recently, INNO-LiPA 
MYCOBACTERIA version 2 (Innogenetics NV, 
Ghent, Belgium), and the GenoType MTBC and 
GenoType Mycobacterium (Hain Lifesciences, 
Nehren, Germany) were introduced; all these are to be 
applied on positive cultures, and all are line-probe 
assays that detect different mycobacteria species 
including MTB.  
A method useful for molecular identification of 
mycobacteria other than tuberculosis is Hsp65PRA 
(PCR-restriction enzyme pattern analysis), which 
combines the amplification of the gene encoding the 
heat-shock protein (hsp) from 65 kDa with the 
digestion of the same, with two restriction enzymes 
BstEII and HaeIII. Using this method, it is possible to 
identify, in addition to M. tuberculosis complex, more 
than 50 species of mycobacteria other than 
tuberculosis on the basis of their characteristic 
restriction profile.  
 
Therapy and susceptibility testing 
Drugs administered for anti-tuberculosis therapy, 
called first-line drugs, were isoniazid (H), 
streptomycin (S), rifampicin (R), pyrazinamide (Z), 
and ethambutol (E). When an MTB strain is resistant 
to more than one antibiotic, in particular to isoniazid 
and rifampicin, the strain is considered multidrug-
resistant (MDR). The presence of MDR strains has 
aggravated the already serious problem of 
tuberculosis, resulting in the use of alternative drugs 
that can be more expensive, less effective, and more 
toxic than those used in traditional therapy. The World 
Health Organization (WHO) revised international 
guidelines for the treatment of tuberculosis in 2010, 
specifically responding to the growing evidence and 
escalating problem of drug-resistant disease 
worldwide. Earlier guidelines emphasized the use of 
two main standardized treatment regimens, one for 
new (previously untreated) cases and one for patients 
with sputum smear-positive disease who had 
previously received treatment (retreatment regimen) 
[29]. The drug combinations used in these two 
regimens differed only by the addition of a single 
drug. New patients with pulmonary TB should receive 
a regimen containing six months of rifampicin: two 
months HRZE and four HR. This regime also applies 
to extrapulmonary TB, but not to TB of the central 
nervous system, bone, or joint, for which some expert 
groups suggest longer therapy. Wherever feasible, the 
optimal dosing frequency for new patients with 
pulmonary TB is daily throughout the course of 
therapy [29]. There are two alternatives: new patients 
with pulmonary TB may receive a daily intensive 
phase followed by a three-times-weekly continuation 
phase (2HRZE/4(HR)3) provided that each dose is 
directly observed. Dosing three times weekly 
throughout therapy (2(HRZE)3/4(HR)3) is another 
alternative, provided that every dose is directly 
observed and the patient is not living with HIV or 
living in an HIV-prevalent setting. In populations with 
known or suspected high levels of isoniazid resistance, 
new TB patients may receive HRE as therapy in the 
continuation phase as an acceptable alternative to HR. 
TB patients whose treatment has failed or other patient 
groups with a high likelihood of multidrug-resistant 
TB should be started on an empirical MDR regimen. 
TB patients returning after defaulting or relapsing 
from their first treatment course may receive the 
retreatment regimen containing first-line drugs 
2HRZES/1HRZE/5HRE if country-specific data show 
low or medium levels of MDR in these patients or if 
such data are not available [29].  
 In recent years, the problem of multidrug 
resistance has been aggravated both by the appearance 
of MTB strains defined as extensively drug-resistant" 
(XDR), which appear to be resistant to isoniazid and 
rifampicin in association with all fluoroquinolones and 
one of three injectable drugs, kanamycin, or amikacin, 
capreomicin. Strains that are resistant to all first-line 
and second-line drugs are considered XDR. Recently, 
six new drugs were developed and analyzed in clinical 
trials [30]. These new drugs include the 
diaryquinolone, TMC-207, which targets 
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mycobacterial ATP synthase; in a phase two clinical 
trial, it greatly increased sputum smear conversion in 
patients with MDR tuberculosis. Nitroimidazoles, such 
as PA-824 and OPC-67683, are equally active against 
drug-susceptible and drug-resistant tuberculosis and 
are also being assessed in clinical trials. Since 
nitroimidazoles are active against both replicating and 
non-replicating organisms, they could potentially 
shorten treatment of active disease and provide 
activity against latent tuberculosis infection. Culture-
based and genotypic methods have been developed to 
detect drug-resistant tuberculosis. Automated liquid 
culture systems and molecular line probe assays are 
recommended by the WHO as the gold standard for 
first-line drug-susceptibility testing (DST) [31]. The 
Food and Drug Administration (FDA) has approved 
the BACTEC MGIT 960 for DST with first-line 
antibiotics. A number of studies have evaluated the 
BACTEC MGIT 960 system for DST of MTB [32]; 
the system was found to be a highly accurate and 
reliable tool for DST. The use of this system has not 
been cleared by the FDA for DST of second-line 
drugs, and thus most laboratories rely on agar 
proportion as the reference standard. Moreover, many 
studies have demonstrated that the performance of 
BACTEC MGIT 960 for DST of second-line drugs 
was comparable to the agar proportion method; the 
system is therefore a reliable tool for detecting 
resistance to second-line drugs [33]. With the purpose 
of detecting drug resistance in a shorter time, several 
molecular approaches have been proposed. There are 
currently two commercially available solid phase 
reverse hybridization assays for the rapid detection of 
drug resistance in MTB: the line probe assay (LiPA) 
(INNO-LiPA Rif TB Assay, Innogenetics, Ghent, 
Belgium) for detecting resistance to rifampicin and the 
GenoType MTBDR Plus (Hain Lifesciences, Nehren, 
Germany) for the simultaneous detection of resistance 
to rifampicin and isoniazid. Recently, the LiPA assay 
has been evaluated for its identification of MTB 
species and detection of mutation related to drug 
resistance in MTB [34]. The results of LiPA 
identification of Mycobacterium species in clinical 
isolates were almost identical to those of conventional 
methods; this assay also was used to directly test 
sputum specimens with a sensitivity of 85.6%. 
Compared with standard DST for the clinical isolates, 
LiPA showed a good sensitivity and specificity for 
detecting rifampin, isoniazid, pyrazinamide, and 
levofloxacin resistance of clinical isolates with a rate 
of 89.7% and 100%, respectively. Its sensitivity and 
specificity for detecting rifampin-, isoniazid-, and 
levofloxacin-resistant isolates in the sputum were both 
100%, and those for detecting isoniazid-resistant 
isolates were 75% and 92.2%, respectively [34]. A 
meta-analysis carried out to assess the accuracy of 
GenoType MTBDR indicates that its sensitivity and 
specificity for rifampicin resistance were 98.1% and 
98.7%, respectively; however, while specificity is 
excellent for isoniazid resistance (99.5%), sensitivity 
estimates were modest and variable. MTBDRsl assay 
(Hain Lifesciences, Nehren, Germany) is a new line 
probe assay for the detection of XDR TB. The test 
simultaneously detects resistance to ethambutol, 
aminoglycosides/cyclic peptides and fluoroquinolones 
through detection of mutations in the relevant genes. 
Its sensitivity for detection of ethambutol resistance 
was low, but its specificity was high for all drugs [35]. 
Besides these commercial kits for the diagnosis of 
drug TB resistance, different manual or experimental 
techniques were described in the literature. For 
example, MODS, NRA, or LRP were evaluated both 
for identification of MTB and determination of 
resistance to anti-tuberculosis drugs. Results of several 
studies have shown that the sensitivity of the MODS 
assay in detecting MDR varies from 72% to 100% 
[16,17,36]. Recently, the performance of NRA on 
Middlebrook 7H11 agar for detection of isoniazid and 
rifampin resistance has been evaluated and compared 
with the direct proportion method on LJ medium 
directly on smear-positive sputum specimens. The 
results of both methods were in 100% agreement for 
detection of R resistance while agreement for H was 
96.4%. These data indicated that direct NRA testing 
on smear-positive sputum specimens by using 7H11 
agar could be used as a fast, reliable, and inexpensive 
method in resource-starved settings [37]. Additionally, 
it has been demonstrated that the NRA method 
provided sensitive detection of resistance both to first- 
and second-line drugs and that it is capable of the 
simultaneous detection of MDR and XDR-TB [38]. 
Evaluations of commercial phage amplification assays 
yielded more variable estimates of sensitivity (range of 
81%-100%) and specificity (range of 73%-100%) 
compared to evaluations of in-house amplification 
assays (sensitivity range 88%-100%, specificity range 
84%-100%). Phage-based assays will require further 
development to maximize interpretable results and to 
reduce technical failures. Tests such as MODS, the 
nitrate reductase assay, and colorimetric reductase 
methods have been conditionally approved by WHO 
for use at national tuberculosis reference laboratory 
levels. 
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Different molecular methodologies to detect the 
anti-tubercular drug resistance were evaluated. Real-
time PCR has been one of the most widely applied due 
to its rapidity, high sensitivity, reproducibility, and 
low risk of contamination. The most common real-
time PCR assays for detecting drug-resistant mutations 
have been developed through two main methods. In 
the first method, a fluorescent signal is generated by 
hybridization of a probe to the target sequence at the 
end of each PCR cycle. The TaqMan probe- and 
molecular beacon-based allele discrimination assays 
belong to this category. Because most of these assays 
require the use of two different fluorophore-labeled 
probes for differentiation of one allele, the cost is 
relatively high and a real-time PCR instrument with 
multiple channels is required. In the second case, 
mutation detection is achieved by melting curve 
analysis. Two major assays, fluorescence resonance 
energy transfer (FRET) probe melting curve analysis 
and high-resolution melting curve (HRM) analysis, 
have been successfully applied to detect drug-resistant 
mutations in MTB [39]. Lou et al. developed a low-
cost, widely applicable real-time PCR assay based on 
melting curve analysis of dually labeled probes, to 
rapidly detect the drug-resistant mutations of MTB. 
Six probes targeting the rpoB 81-bp core region, 
katG315, the inhA promoter, the ahpC promoter, and 
embB306, were designed and validated with clinical 
isolates. A comparison of the results with the 
sequencing data showed that all mutations covered by 
the six probes were detected with 100% sensitivity and 
100% specificity [39]. Liu et al. developed a simple 
and widely applicable assay for detecting mutations 
associated with second-line drug resistance in 
Mycobacterium tuberculosis. Three dually labelled 
probes targeting gyrA, rrs, and the promoter of eis 
were designed to detect resistance to fluoroquinolones 
and second-line injectable agents (capreomycin, 
amikacin, and kanamycin). A triplex reaction with all 
three probes and corresponding primers was first 
tested against 13 isolates with different mutations in 
the targeted regions. The triplex assay was applied to 
109 second-line drug-resistant isolates and the results 
were compared with the sequencing data. The 
detection results of 109 isolates were 100% 
concordant with sequencing data [40]. 
Another PCR-based method of detecting TB drug 
resistance is the single-stranded conformational 
polymorphism (SSCP) analysis, which involves 
amplification by PCR of a segment of the gene 
encoding for the specific drug target and comparison 
of PCR products of drug-sensitive and drug-resistant 
strains by SSCP, in which mutations usually result in 
an altered pattern. This technique is relatively simple, 
but its sensitivity and specificity have been questioned. 
Pyrosequencing is a semi-automated sequencing 
method based on real-time monitoring of DNA 
synthesis, optimized to analyze short DNA sequences. 
It is based on the quantitative detection of released 
pyrophosphate during DNA synthesis. In a cascade of 
enzymatic reactions, light is generated at intensities 
proportional to the numbers of incorporated 
nucleotides [41]. Pyrosequencing has previously been 
described as a method for detecting drug resistance in 
MTB [41]. In comparison to phenotypic DST, the 
pyrosequencing method demonstrated high specificity 
(100%) and sensitivity (96.4%) for detection of MDR 
MTB as well as high specificity (99.3%) and 
sensitivity (86.9%) for detection of XDR MTB [41]. 
DNA microarrays have been applied widely in 
fundamental research, human genetics, infectious 
disease diagnosis, genotyping, genetic expression 
monitoring, pharmacogenomics, environmental 
control, and in the identification and detection of 
mutations in genes responsible for drug resistance. 
High-density oligonucleotide arrays have been used 
for parallel species identification and the detection of 
mutations that confer rifampicin resistance in 
mycobacteria, and more specifically for the detection 
of MTB strains resistant to rifampicin or isoniazid, 
kanamycin, streptomycin, pyrazinamide, and 
ethambutol. Aragon et al. developed a fast low cost 
and low density DNA microarray (LCD array) for the 
detection of mutations that confer isoniazid or 
rifampicin resistance in MTB isolates. They observed 
that LCD was 100% concordant with the sequencing 
data for H resistance and 93.8% concordant for R 
resistance [42]. A sensitive and specific microarray 
was designed by Yao et al. to detect mutations in the 
rifampin resistance determining region of rpoB and 
loci in katG and inhA associated with H resistance. 
They indicated that 100% of rifampicin-resistant MTB 
strains analyzed had rpoB mutations. Of the total 50 
H-resistant isolates, 82% had a katG315 mutation and 
18% had an inhA mutation. All the mutations detected 
by the microarray method were also confirmed by 
conventional DNA sequencing. It has been 
demonstrated that the microarray is an efficient, 
specialized technique and can be used as a rapid 
method for detecting rifampin and isoniazid resistance. 
More recently, Zhang et al. assessed the performance 
of the CapitalBio DNA microarray in the detection of 
H and R resistance in spinal tuberculosis compared 
with the BACT/MGIT 960 system. The DNA 
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microarray had a sensitivity of 88.9% and a specificity 
of 90.7% for R resistance, and a sensitivity of 80.0% 
and a specificity of 91.0% for H resistance. The mean 
turnaround time of MTB species identification and 
drug resistance detection using the DNA microarray 
was 5.8 hours [43]. 
 
Urine-baseddiagnostic test 
M. tuberculosis antigen detection has long been 
viewed positively as an option for TB diagnosis. A 
number of mycobacterial antigens can be detected in 
the urine of patients with pulmonary TB; the most 
promising of these is the cell wall lipopolysaccharide 
lipoarabinomannan (LAM) [44]. An enzyme-linked 
immunosorbent assay (ELISA) that detects LAM has 
been developed. Although the sensitivity of this test 
has been disappointing in non-HIV-infected patients, 
moderate sensitivity and high specificity has been 
observed in HIV-infected patients with advanced 
immunodeficiency [45]. This assay could provide 
evidence of tuberculosis in patients with advanced 
HIV infection being screened in antiretroviral therapy 
clinics and in those with possible disseminated 
disease. Although the sensitivity of many tuberculosis 
diagnostic tests declines steeply in HIV-infected 
patients with more advanced immunodeficiency, 
paradoxically, the sensitivity of the LAM ELISA 
increases at lower CD4 lymphocyte cell counts [45]. 
The commercially available LAM ELISAs are 96-well 
plate format sandwich assays that employ highly 
purified polyclonal antibody preparations. This format 
of the assay is not suitable for use in resource-limited 
settings due to infrastructure limitations and the 
requirement for samples to be prepared and batches to 
be processed in centralized laboratories. However, 
using the same antibody preparations, a simple lateral-
flow version of the assay has been produced as a 
point-of-care test. Determine TBLAM Ag (Determine 
TB-LAM, Alere, Waltham, USA) is an 
immunochromatographic assay in which the captured 
antibodies are adsorbed onto the nitrocellulose 
membrane of the test strip and the detection antibody 
is labeled by conjugation to colloidal gold particles. In 
a study evaluating this test as a tool for tuberculosis 
screening among patients enrolling in an antiretroviral 
therapy clinic in South Africa, the sensitivity was 
equivalent to that of the ELISA format of the assay, 
and specificity was 98% overall and stratified by CD4 
cell count in all patient subgroups [46]. The same 
authors more recently demonstrated that the low-cost 
point-of-care urine test for LAM rapidly diagnoses a 
sub-group of cases with advanced HIV-associated TB 
and poor prognosis, and if used in combination with 
laboratory-based diagnostics, treatment delays would 
decrease and survival might be improved [47]. Studies 
in appropriate clinical populations are providing new 
insights into the real utility of this assay; it is now 
emerging as an important tool that may serve to 
greatly expedite TB diagnosis and treatment in those 
with advanced HIV-associated immunodeficiency, 
potentially reducing mortality risk. 
 
Immunochromatografic assay 
Correct mycobacteria identification is crucial for 
the effective treatment of TB. Positive mycobacterial 
cultures do not necessarily mean they are positive for 
MTB complex; the culture needs to be identified to 
discriminate MTB complex from non-tuberculous 
mycobacteria (NTM). 
Usually, most laboratories in resource-limited 
settings use the labor-intensive standard biochemical 
tests to identify MTB complex, which require 
subculture of mycobacteria on solid media and delays 
results for several weeks. This process increases the 
turnaround time for reporting positive results. 
Commercial diagnostic methods employing nucleic 
acid amplification may provide rapid results for the 
identification of MTB complex, but most of them are 
designed for semi-automated use; furthermore, they 
are still time consuming and require other laboratory 
equipment. There are currently three commercial tests 
for the rapid identification of MTB complex from 
positive cultures based on the same 
immunochromatographic technology: the Capilia test 
(Tauns Laboratories, Numazu, Japan), the SD Bioline 
TB Ag MPT64 Rapid Test (Standard Diagnostics, Inc, 
Kyonggi-do, South Korea), and the BD MGIT TBc 
Identification test (BD Diagnostic Systems, Sparks, 
USA). All detect the antigen MPT64 for rapid 
discrimination between MTB complex and NTM. The 
Capilia test is not widely available in the market; it is 
only available through FIND (Foundation for 
Innovative New Diagnostics, Geneva) and to a 
restricted number of countries, especially  countries 
with a high TB burden. SD Bioline TB Ag MPT64 
Rapid Test and the BD TBc ID test are available in the 
market and can be obtained without restrictions. 
The Capilia test was evaluated in resource-limited 
settings for rapid identification of MTB from 
BACTEC MGIT 960 and BACTEC 9120 systems 
[48]. One thousand samples from pulmonary and 
disseminated TB were cultured in automated 
BACTEC MGIT 960 and BACTEC 9120 blood 
culture systems. The overall sensitivity and specificity 
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for Capilia TB assay for identification of MTB were 
98.4% and 97.6%, respectively; additionally, Capilia 
TB was cheaper, easier to perform, and had a shorter 
turnaround time (20 minutes) [48]. A study in Zambia 
and South Africa demonstrated that sensitivity and 
specificity of Capilia TB assay was 99.6% and 99.5%, 
respectively, and that this test is inexpensive and can 
be used in resource-limited settings [49]. When the SD 
Bioline Ag MPT64 Rapid Test was evaluated for the 
identification of MTB, the assay showed excellent 
sensitivity and specificity. Martin et al. evaluated the 
performance of the TBc ID test. Ninety-two cultures 
were evaluated and the sensitivity and specificity of 
the TBc ID test was 98.5% and 100%, respectively. 
The researchers indicated that the assay might have 
yielded false negative results because of the mutation 
in the MPT64 gene or because the MTB cell numbers 
in the culture were too low to produce sufficient 
MPT64 antigen detection [50]. Po-Liang Lu et al. 
reported less sensitivity and specificity (95.2% and 
99.2%, respectively) and also indicated that false 
negative results can occur when there is a mutation in 
the MPT64 gene or when its amount is low [51]. 
Overall data indicate that the TBc ID test is a very 
simple way to identify the presence of MTB complex 
in liquid cultures, which could provide a good 
alternative to the time-consuming biochemical 
identification tests and more expensive molecular 
tests. Moreover, integration of solid and liquid cultures 
and using an additional molecular method can yield a 
sensitivity up to 100% for MTB complex detection. 
All immunochromatografic assays have several 
advantages and are destined to be used in all 
laboratories, particularly in endemic areas. 
 
Cricetomys rats: a potential diagnostic system 
Tuberculosis diagnosis in regions with limited 
resources depends on microscopy with insufficient 
sensitivity. Rapid diagnostic tests of low cost but high 
sensitivity and specificity are needed for better point-
of-care management of TB. Giant African pouched 
rats (Cricetomys gambianus) are used operationally to 
detect land mines. A nonprofit humanitarian 
organization, APOPO, located in Morogoro, Tanzania, 
is responsible for the use of rats as mine-detection 
animals and is also exploring other humanitarian 
applications for the rats, using the animals to detect 
tuberculosis in humans. These large and long-lived 
rats, which are native to much of Africa and have an 
excellent sense of smell, detect TB by sniffing sputum 
samples. They are trained to respond consistently in 
one way (pause) if the samples contains the TB 
bacillus (positive) and respond in another way (not 
pause) if the sample does not contain the bacillus 
(negative) [52]. Each rat can test hundreds of samples 
each day, allowing for inexpensive testing. The odor 
uniquely associated with MTB constitutes a signal for 
the rats that emit an easily observed indicator response 
when they smell a sputum sample positive for MTB. 
The training of Cricetomys rats for TB diagnosis 
commences at four weeks of age. The training 
duration required for rats to qualify for diagnosis of 
TB ranges between six and nine months. Several 
studies have described the use of rats as TB detectors. 
Weetjens et al. used a cage with 10 sniffing holes and 
put in a cassette carrying 10 sputum samples. Rats 
were trained to sniff each consecutive sample and 
indicate TB positives by fixing their nose for five 
seconds at the sniffing hole. Eighteen rats were able to 
discriminate positive from negative sputum with a 
daily sensitivity ranging from 72% to 100%. Daily 
false positives ranged from 0.7% to 8.1% [53]. Poling 
et al. evaluated 23,101 sputum samples; the specimens 
were first evaluated by microscopists and then by rats. 
Microscopists identified 2,487 sputum samples as TB 
positive; the rats verified these findings and identified 
2,274 samples as TB positive. The rats also identified 
as positive an additional 927 TB samples initially 
indicated as negative but found in second microscopy 
to contain the bacillus. The authors concluded that the 
use of pouched rats for TB detection in developing 
countries certainly warrants further research [54]. 
Mgode et al. evaluated rats’ ability to discriminate 
between clinical sputum containing other 
Mycobacteria spp. and non-mycobacterial species of 
the respiratory tract. The authors indicated that MTB 
produces specific volatiles that are not produced by 
NTM and other respiratory microorganisms 
investigated in this study [55]. They suggested that a 
defined blend of MTB-specific volatiles apparently 
allows trained rats to discriminate TB-positive from 
TB-negative sputa for accurate odor diagnosis of TB. 
These findings are potentially relevant to initiatives to 
develop a point-of-care test for rapid TB diagnosis. 
Another recent study investigated the odor volatiles of 
MTB detected by rats in reference to MTB, non-
tuberculous mycobacteria, Nocardia sp., Streptomyces 
sp., Rhodococcus sp., and other respiratory tract 
microorganisms spiked into MTB-negative sputum. 
Thirteen compounds were specific to MTB and 13 
were shared with other microorganisms. Rats 
discriminated a blend of MTB-specific volatiles from 
individual and blends of shared compounds. The rats’ 
sensitivity for typical TB-positive sputa was 99.15%, 
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with 92.23% specificity and 93.14% accuracy. 
Overall, these data indicated that the use of trained 
sniffer rats for TB detection is a potentially faster 
screening method and is at least as sensitive as smear 
microscopy. This method could therefore be suitable 
for active case finding, especially where large numbers 
of samples are to be analyzed in resource-limited 




Tuberculosis is one of the main causes of mortality 
worldwide and most cases occur in resource-limited as 
areas of Asia and Africa. Poverty is one of the biggest 
factors influencing TB diagnosis in these countries. 
Consequently, the implementation of new diagnostics 
for the more accurate and rapid diagnosis of TB can be 
extremely costly for resource-poor countries. 
In many low-resource high-burden countries, 
microscopic examination of Ziehl-Neelsen stained 
sputum specimens is often the only tuberculosis test 
available due to its low cost (0.50 US dollar) for two 
sputum smear examinations. However, this method 
lacks sensitivity and performs poorly in young 
children and individuals who are 
immunocompromised. Also in these countries, many 
smear microscopy laboratories are single rooms and 
understaffed with poorly maintained microscopes, and 
some of these laboratories lack consistent sources of 
electricity and clean water.  
Culture remains the gold standard for the diagnosis 
of TB. Different liquid broth automated systems have 
been developed and they have been essential for 
strengthening TB diagnoses, as they have a good 
sensitivity for isolation of mycobacteria and treatment 
in many countries [56]. The WHO recommends 
expanded use of liquid culture systems in resource-
constrained settings; however, purchasing, 
maintaining, or providing large rooms to safely 
accommodate these instruments can be extremely 
difficult for most of the public health laboratories in 
these countries. Consequently, most resource-poor 
countries depend on LJ egg-based solid medium for 
the detection of growth of MTB isolates. LJ medium 
can be prepared locally, has good buffer capacity, has 
a shelf-life of several months when refrigerated, and 
supports the growth of most mycobacterial species. 
Chihota et al. compared the MGIT system with LJ 
medium, considering MGIT’s cost effectiveness. Cost 
per culture on LJ, MGIT, and MGIT+LJ was, 
respectively 12.35, 16.62, and 19.29 US dollars [57]. 
These costs per culture were lower than estimates from 
an another study in Zambia, where base-case 
throughput was substantially lower and overhead 
costs, which included transport and all resources not 
directly involved in performing the culture, were 
substantially higher. Comparable costs in this study 
were slightly higher than estimates from Dowdy et al., 
probably due to the assumption of available 
infrastructure capacity with no additional cost used in 
the Dowdy study [58].  Generally, MGIT costs are 
high, but MGIT gives a higher yield and faster results 
compared with solid media. The MGIT system is 
sensitive to throughput and its use facilitates high 
throughput that few manual systems can match, and is 
therefore well suited to busy regional laboratories but 
is clearly less appropriate for a district laboratory 
receiving 30 samples per week. 
Kidneye et al. compared micro-broth culture in 
microplate wells, where MTB growth was detected by 
microscopic observation, with LJ solid media. The 
first method is early, feasible, and inexpensive for 
detection of pulmonary tuberculosis. The cost was 
4.56 US dollars per sample versus 11.35 US dollars 
for LJ solid media [59]. A limit of micro-broth culture 
is that an inverted light microscope to visualize the 
characteristic cording growth of MTB is required, 
which is not a standard piece of lab equipment, and 
few labs have this tool. Consequently, despite its low 
cost and good performance in the detection of MTB 
growth, the routine use of the broth culture method in 
resource-poor settings depends on the lab availability 
of the inverted light microscope. Several rapid 
molecular tests have been proposed for the rapid 
diagnosis of tuberculosis. Both in-house and 
commercial assays are available, and both have been 
evaluated in numerous studies performed in different 
settings with good sensitivity and specificity. 
Molecular test are also available for the detection of 
drug resistance; they have been evaluated both for 
first- and second-line antitubercular drugs. Xpert 
MTB/RIF is a new molecular assay that provides 
simultaneous detection of MTB and R resistance. This 
assay was specifically recommended for use as the 
initial diagnostic test for suspected drug-resistant or 
HIV-associated pulmonary tuberculosis. By June 
2012, two-thirds of countries with a high tuberculosis 
burden and half of the countries with a high multidrug-
resistant tuberculosis burden had incorporated the 
assay into their national tuberculosis program 
guidelines. The Foundation for Innovative and New 
Diagnostics negotiated a discounted pricing structure 
applicable to145 high-burden and developing 
countries. A four-module GeneXpert platform and 
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linked computer costs about US$17.00 (over 60% 
cheaper than elsewhere).  
Thanks to funding from different organizations, 
the cost per cartridge was set at 9.98 US dollars 
beginning Aug 6, 2012, for the next 10 years [60]. 
Xpert MTB/RIF assay implementation for routine use 
in resource-limited settings has potential benefits as 
well as challenges. The most important benefit is the 
increase in TB case detection with reduction in 
mortality, morbidity, and TB transmission. Molecular 
platforms can also reduce the time to diagnosis and 
treatment, and reduce the need for culture and 
biohazard. However, implementation of the Xpert 
MTB/RIF in resource-limited settings, especially in 
peripheral health facilities, has required investments in 
training of operators and laboratory staff. 
Environmental limitations (stable and regular 
electricity, adequate room temperature) and difficulties 
involved in supply and maintenance are others factors 
that limit the use of this method. It should be possible 
to offer the test fairly rapidly at the main provincial or 
regional referral hospitals, where more services can 
and should be offered to patients. Alternative methods 
for diagnosing drug resistance such as NRA assays 
and the MODS method could be implemented if an 
inverted light microscope is available. Both can also 
be used as culture assays, and both are low cost non-
commercial tests (ranging in cost from 3.00 to 4.00 US 
dollars and 1.40 to 3.50 US dollars, respectively), have 
standardized methods and protocols, use minimal 
equipment, and are readily available. Nevertheless, 
NRA on solid media uses a modified LJ media and 
should thus be straightforward for laboratories already 
performing LJ cultures, although the need for repeated 
opening of cultures demands category III level 
laboratory biosafety. With the MODS assay, biosafety 
is good because cultures are never opened; thus, it can 
be performed in a category II facility. Other tests such 
as the urine-based diagnostic assay and 
immunochromatografic test are rapid and inexpensive 
methods (3.50 and 2.03 US dollars, respectively) for 
diagnosing tuberculosis. In particular, the urine-based 
test, despite its apparent sub-optimal sensitivity, may 
be an important tool that my serve to greatly expedite 
TB diagnosis and treatment in those with advanced 
HIV-associated immunodeficiency, potentially 
reducing mortality risk. In recent years, operant 
discrimination training procedures have been used to 
teach giant African pouched rats to detect tuberculosis 
in human sputum samples. Available data suggest that 
pouched rats, which can evaluate many samples 
quickly, are sufficiently accurate in detecting TB to 
merit further investigation as a diagnostic tool. 
Budgetary constraints are a major consideration 
that has affected the choice of diagnostic assay in 
developing countries. In limited settings, a cost-
effectiveness analysis of the introduction of a new TB 
diagnostic is very important. The choice between five 
10 US dollars tests or one equally reliable 50 US 
dollars test might appear straightforward. However, if 
the 50 US dollars test provides the result for one 
patient at particular high risk in one day, this might be 
more useful than having results for five people one 
week later.  
Modeling studies have estimated that 400,000 lives 
could be saved each year with the introduction of an 
accurate, rapid, and widely available TB diagnostic 
system with a sensitivity greater than 85% for both 
smear-positive and smear-negative cases, and 97% 
specificity. In addition, modeling has shown that 
expanding TB culture and drug susceptibility testing 
could lead to reduced mortality, especially for those 
patients infected with MDR-TB, and there is 
significant potential that TB culture and new 
diagnostics could be effective and cost-effective for 
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